✦ LIBER ✦

Retinoic Acid Metabolism Blocking Agents (RAMBAs) for Treatment of Cancer and Dermatological Diseases

✍ Scribed by Vincent C. O. Njar; Lalji Gediya; Puranik Purushottamachar; Pankaj Chopra; Tadas Sean Vasaitis; Aakanksha Khandelwal; Jhalak Mehta; Carlic Huynh; Aashvini Belosay; Jyoti Patel

Publisher: John Wiley and Sons
Year: 2006
Weight: 8 KB
Volume: 37
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200637236

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: Synthesis of Liazal

ChemInform Abstract: Synthesis of Liazal10s, a Retinoic Acid Metabolism Blocking Agent (RAMBA) with Potential Clinical Applications in Oncology and Dermatology.

✍ E. FREYNE; A. RAEYMAEKERS; M. VENET; G. SANZ; W. WOUTERS; R. DE COSTER; J. VAN W 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 36 KB

The emerging role of retinoids and retin

The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer

✍ Wilson H. Miller Jr. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

BACKGROUND. Although significant advances have been made in the treatment of some malignancies, the prognosis of patients with metastatic tumors remains poor. Differentiating agents redirect cells toward their normal phenotype and therefore may reverse or suppress evolving malignant lesions or preve

Potent and Selective [2-Imidazol-1-yl-2-

Potent and Selective [2-Imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl] -dimethyl-amines as Retinoic Acid Metabolic Blocking Agents (RAMBAs).

✍ Mark J. Mulvihill; et al. et al. 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 21 KB

Bile acids for babies? Diagnosis and tre

Bile acids for babies? Diagnosis and treatment of a new category of metabolic liver disease

✍ Frederick J. Suchy 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 521 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin